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INTRODUCTION
History and concept
The many origins and sources of inspiration of the no-
tion of empowerment can be traced back to such varied 
domains as feminism, Freudian psychology, theology, 
the Black Power movement, and Gandhism. Another 
important influence to the empowerment “philosophy” 
appears to be the work of Paolo Freire and his concept 
of “popular education” developed in the 1960s, which 
became influential in development practices in Latin 
America in the 1970s, associated particularly with lit-
eracy projects [1]. However, it is not until the 1970s, 
especially the 1976 publication of Black empowerment. 
Social work in oppressed communities by Barbara Solo-
mon, that the term formally comes into use by social 
service providers and researchers. In the 1980s, empow-
erment was seen, for the most part, as a radical project 
of social transformation, to enable otherwise excluded 
social groups to define and claim their rights collectively 
[2]. A notable example related specifically to the field 
of health and people living with a disease, is the self-
empowerment movement of people living with AIDS 
during the 1980s, particularly the drafting of their 1983 
“Denver Principles” where the idea that personal ex-
periences should shape the AIDS response was first 
voiced [3] and in which they made their seminal dec-
laration stating: “We condemn attempts to label us as 
‘victims’, a term which implies defeat, and we are only 
occasionally ‘patients’, a term which implies passivity, 
helplessness, and dependence upon the care of others. 
We are ‘People With AIDS’ ” [4]. It is therefore in the 
context of various social movements that the word ‘em-
powerment’ begins to be used increasingly in research 
and intervention concerning groups experiencing mar-
ginalisation, such as African Americans, women, gays 
and lesbians, and people with disabilities. 
From this historic overview, it appears that empower-
ment refers in essence to principles such as the abil-
ity of individuals and groups to act in order to ensure 
their own well-being or their right to participate in any 
decision-making that concerns them. However, em-
powerment is a complex concept that has been used in 
different ways. Gibson suggested that “Empowerment 
is […] easier understood by its absence: powerlessness, 
helplessness, hopelessness, alienation, victimisation, 
subordination, oppression, paternalism, loss of a sense 
of control over one’s life and dependency” [5]. In addi-
tion, not only are we lacking an agreed upon definition 
of “empowerment”, but the word itself does not trans-
late easily or equally. For example, in both German and 
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Abstract
The notion of empowerment is linked to patients’ everyday life and is the base allowing 
for the patient engagement through which individuals and communities are able to ex-
press their needs, are involved in decision-making, take action to meet those needs. In 
the field of rare diseases, empowerment strategies have greater value due to low preva-
lence, lack of expertise, poor quality of life. Avenues to patient empowerment are: health 
literacy and capacity-building; shared decision-making; support to self-management. Pa-
tient empowerment is recognised as key enabler in creating sustainability as addressing 
challenges faced by modern healthcare systems in terms of effectiveness, access and 
resilience. It is recommended to develop a comprehensive EU roadmap on patient em-
powerment including specific recommendations, taking stock of good practices. This 
holistic approach should lead to a society where all actors are fulfilled human beings and 
unmet needs are addressed in compliance with fundamental human rights.
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French, the English expression “to empower” can be 
translated into two different verbs: ermächtigen/auto-
riser (which suggests “power over”) on the one hand, 
and befähigen/rendre capable (“power to”) on the other 
[2]. There are other possibilities for a French transla-
tion: the Quebec French dictionary uses the word 
autonomisation; the World Bank [6] uses the words 
“demarginalisation” and “integration”. Empowerment 
is also found in the literature as “renforcement des ca-
pacités et participation” [6].
Another issue of definition is the distinction between 
empowerment being a process/approach or being a 
goal/outcome, although these two concepts are not nec-
essarily disparate: The World Bank, for instance, defines 
“empowerment as the process of enhancing the capacity 
of individuals or groups to make choices and to trans-
form those choices into desired actions, which both 
build individual and collective assets, and improve the 
efficiency and fairness of the organisational and institu-
tional context which govern the use of these assets” [7].
In the field of healthcare, the term patient empower-
ment gained prominence as part of a move away from 
paternalism towards more equitable and collabora-
tive models of healthcare delivery, with the potential 
for improving cost-effectiveness of care, especially for 
people affected by long term conditions [8]. In this 
sense, empowerment is viewed as a process of “activat-
ing” patients, who as a result of “rejecting the passivity 
of sick role behaviour and assuming responsibility for 
their care (…), are more knowledgeable about, satisfied 
with, and committed to their treatment regimens” [9]. 
The European Patients’ Forum explains this distinction 
between the individual (patient) level and the collec-
tive (patient community) level as the difference be-
tween gaining personal skills in the former, and creating 
mutual support groups, identifying issues through the 
sharing of information and creating a coalition with po-
tential for advocacy in the latter [10]. Another impor-
tant nuance highlighted in the EU-funded EMPATHiE 
project (“Empowering Patients in the Management 
of Chronic Diseases”) is the fact that “an empowered 
patient has control over the management of their con-
dition in daily life” and they “develop self-confidence, 
self-esteem and coping skills to manage the physical, 
emotional and social impacts of illness in everyday life” 
(www.eu-patient.eu/contentassets/543c15ed8f8c40f69
2030a0a0d51b8e2/empathie_frep_en.pdf). Therefore, 
patient empowerment can go beyond solely changing 
the way one copes and manages healthcare strategies, 
but also enter the realm of everyday life.
The fact that patient empowerment as a process can 
occur at the individual level and at the collective level, as 
well as in the medical context and outside of it, means 
that patient empowerment can have an impact at: micro 
(patient) level, in terms of improved health, greater sat-
isfaction with the treatment option and better quality 
of life and psychological state; at macro (community) 
level in terms of quality of health and social services and 
design of interventions responding better to needs; and 
at policy level in terms of policy prioritisation, design, 
and cost-effectiveness [10]. In view of these elements, 
four components can be considered as fundamental to 
the process of patient empowerment: 1) understanding 
by the patient of his/her role; 2) acquisition by patients 
of sufficient knowledge to be able to engage with their 
healthcare provider; 3) patient skills; and 4) the pres-
ence of a facilitating environment. In sum, although the 
term can have different meanings and interpretations, 
patient empowerment generally refers to the process that 
allows an individual or a community to gain the knowl-
edge, skills, and attitude needed to make choices about 
their care.
In the field of rare diseases this process of empower-
ment takes on an even greater value. First off, because, 
due to the low prevalence and the lack of expertise and 
adequate information, the patient is forced to become 
knowledgeable about his own disease state. Moreover, 
people living with a rare disease are often at high risk 
of experiencing poor quality of life, including increased 
levels of anxiety, depression, pain, fatigue and limited 
ability to participate in society. The results of the Rare-
Barometer survey “Juggling day care and daily life” [11], 
developed in the framework of the InnovCare project 
(www.innovcare.eu), with over 3000 respondents, pro-
vides detailed evidence of this reality. This has made it 
clear that, while each disease may have its own set of 
characteristics and health impacts, people living with a 
rare disease often share similar experiences and chal-
lenges – including limited information, no treatment, 
lengthy times to diagnosis and isolation. In addition, it 
is often the very rarity of rare diseases that has left them 
largely disregarded by the research or medical commu-
nity and policy makers.
To overcome these difficulties, empowerment, de-
fined as an action-oriented notion with the focus on 
removal of formal or informal barriers, and on trans-
formation of relations between communities and in-
stitutions, becomes a necessity for people living with a 
rare disease. It becomes crucial to look at this group 
collectively, rather than at each rare disease indepen-
dently, to identify the common problems and gather 
the actors (critical mass) for joint actions (collaborative 
work) towards the strengthening of the actors’ abilities 
and their recognition in the social field. This realisation 
has led to patient empowerment being effectively ap-
plied in the rare diseases community over the last few 
decades. Empowerment strategies in the rare diseases 
community include improving access to information on 
the basis of indigenous knowledge, finding supportive 
groups, and establishing dialogues, and they have led 
to reduced social exclusion and health disparities, and 
built a sense of community [12]. These strategies occur 
at both the individual (patient) level as well as at the 
community level. 
Firstly, it is important to highlight that individual em-
powerment of people living with a rare disease has been 
mediated by the rapid growth of web-based health-re-
lated information, notably by:
• the possibility of establishing or joining online cross-
border communities for people with the same disease 
or the same problem, of which the platform of online 
patient communities RareConnect.org is a prominent 
example in terms of both disease and geographical 
coverage;
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• and by the availability of help lines and other sup-
port services often offered by patients’ organisations. 
In particular, help lines, supported by the European 
Network of Help Lines for Rare Diseases (www.
eurordis.org/content/help-line-services), play an es-
sential role in providing the often lacking informa-
tion that patients face, especially in the absence of 
disease-specific patient organisations. 
In addition, another key component of individual 
empowerment is the ability to self-care, including the 
self-management of the condition. This ability of the 
patient to deal with all the elements of its condition, 
including symptoms, treatment, physical and psycho-
social consequences, and lifestyle changes, requires 
the coordinated approach between physicians, patients, 
care-givers, and health care organisations. Self-manage-
ment support allows the development of confidence, 
self-efficacy and skills to control daily life. In the case of 
people living with rare diseases, it is often the case that 
patients themselves and in particular, family members, 
act as primary carers. However, research reveals that 
self-management and the collective support required to 
achieve it is far from being an easy task [11].
Secondly, it is crucial to point out the key role of pa-
tients’ organisations. “Rare disease patient organisations 
have been created as a result of experience gained by 
patients and their families from being so often exclud-
ed from health care systems and thus having to take 
charge of their own disease themselves. The scientific 
community’s inadequate knowledge of rare diseases 
and the scarce attention given to them by national com-
petent authorities and the pharmaceutical industry has 
led to the creation of associations of patients and par-
ents. Rare disease patient associations aim at gathering, 
producing and disseminating the limited existing infor-
mation on their disease and making patients and par-
ents voices’ heard. Their actions have already ensured 
progress in healthcare and social assistance provided to 
patients and carers, development of treatments, and in 
raising public awareness of rare diseases” [11]. In this 
sense, patient organisations act at both the individual 
and collective levels of patient empowerment. In fact, 
the very nature of rare diseases patient organisations 
places “patient empowerment” at the core of their mis-
sion. For EURORDIS-Rare Diseases Europe, the EU 
alliance of rare disease patient organisations, “patient 
empowerment” is one of the three key components of 
its tripartite mission and is centred on information shar-
ing, community-building, networking opportunities for 
members and capacity-building for patients.
MATERIAL AND METHOD
The document is the result of a review of literature 
on topic, patient advocates’ testimonials, EU policy 
documents and legislation, results of surveys performed 
under the RareBarometer survey programme (www.
eurordis.org/voices), as well as consultation with EU-
RORDIS (www.eurordis.org) European Public Affairs 
Committee (EPAC). The brief, after shedding light on 
the concept of “patient empowerment” and its historic 
development, tries to define the way in which patient 
empowerment is implemented and to identify the link 
between patient empowerment and equity, resilience 
and sustainability of healthcare systems.
RESULTS
a) What is an empowered patient?
The Alma Ata Declaration issued by the World Health 
Organisation (WHO) as far back as 1978 stated that: 
“The people have the right and duty to participate indi-
vidually and collectively in the planning and implemen-
tation of their healthcare” [13]. In 2006, the Council of 
the European Union declared that patient involvement 
is a common operating principle in the health systems 
of the European Union [14]. However, today this is still 
not the patient’s experience on a daily basis. But, what 
is an empowered patient? And what is the distinction 
between an empowered and an engaged patient?
In health care, the rapid proliferation of health infor-
mation on the Internet has resulted in more patients 
turning to the Internet, particularly social networks such 
as PatientsLikeMe (www.patientslikeme.com/), Con-
nected Living (www.connectedliving.com/) or RareCon-
nect, specifically for rare diseases) as their first source of 
health information. This rapid evolution of digital tech-
nologies has shifted the focus to sharing and co-creation 
of knowledge. This has radically changed the way pa-
tients interact with institutions, with the media and with 
other stakeholders in the reference context.
However, the information patients access indepen-
dently will vary in quality. This wealth of information 
can be very powerful, but it can also be confusing, in 
particular if the individual patient is not able to use ef-
fectively the information. In this respect, empowering 
patients means enabling them to make good use of their 
available knowledge by providing tools, techniques, and 
support that allow them to actively participate in the 
management of their health and life if they wish so. 
However, empowerment is not a simple process, nor is 
it necessarily linear, and it is not a process that can be 
imposed, only facilitated [10].
Moreover, it is not always easy to distinguish clearly 
between patient empowerment and patient involve-
ment/engagement. Generally speaking, only once a 
patient is empowered, can a patient be engaged, the 
difference between the two being that the former (pa-
tient empowerment) is the common base allowing for 
the latter (patient engagement). The concept of pa-
tient involvement refers specifically to the rights and 
the benefits of patients to have a central position in the 
healthcare process, it goes beyond the availability of in-
formation or health literacy: it is about the interaction 
between the patient and the healthcare provider and 
encompasses a wide range of different aspects. 
Recently, the EU-funded EMPATHiE project devel-
oped the following working definition of an empowered 
patient which combines both terms: “An empowered 
patient has control over the management of their condi-
tion in daily life. They take action to improve the quality 
of their life and have the necessary knowledge, skills, 
attitudes and self-awareness to adjust their behaviour 
and to work in partnership with others where necessary, 
to achieve optimal well-being. Empowerment interven-
tions aim to equip patients (and their informal caregiv-
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ers whenever appropriate) with the capacity to partici-
pate in decisions related to their condition to the extent 
that they wish to do so; to become “co-managers” of 
their condition in partnership with health professionals; 
and to develop self-confidence, self-esteem and coping 
skills to manage the physical, emotional and social im-
pacts of illness in everyday life” [10].
Additionally, and in line with the scheme illustrated 
by Christopher Rissell [15], the European Patients’ 
Forum (EPF) proposes a definition of empowerment 
that includes the significant role of patient organisa-
tions in advocating for the patient perspective at policy 
level, this incorporating both the individual (patient) 
and the collective (patient community) dimension of 
empowerment.
Several countries have put patients at the centre of 
their healthcare policy [16]. The NHS in the UK, for 
example, has promoted the concept of patient involve-
ment using the well-known slogan: “No decision about 
me without me” [17]. At the EU level, a remarkable 
example of the adoption of the latter principle is the 
2015 Addendum to EUCERD Recommendations on 
European Reference Networks (ERNs) for Rare Dis-
eases (31 January 2013) whereby “Patients and patient 
representatives should play an integral role in the de-
cision and opinion making process in RD ERNs and 
be involved in structural and clinical network activi-
ties. It is recommended that RD ERNs demonstrate 
meaningful patient involvement, patient-centredness 
and empowerment through recognition of the role of 
patients, as experts by experience and co-producers of 
knowledge, in RD ERN structural and clinical activities 
and therefore demonstrate meeting the legal require-
ments in the Delegated Acts [18]”. This principle has 
been translated into the governance of the existing 24 
ERNs and the involvement of ePAGs (European Pa-
tient Advocacy Groups) in each ERN.
To sum up, empowerment is “a process through 
which individuals and communities are able to express 
their needs, present their concerns, devise strategies 
for involvement in decision-making, and take political, 
social, and cultural action to meet those needs [10]”. 
In particular, for rare disease patients, this translates 
in a process leading to collective intelligence to solve 
complex problems, it is continuous production and im-
provement of information, knowledge expertise as well 
as well as support and solutions [19].
Empowerment of patients is a task which involves 
and encourages interaction of communities, health 
care professionals, policy-makers and all other civil 
society actors with respect to health and wellbeing of 
individuals. “Empowering patients means providing 
them with the opportunities and the environment to 
develop the skills, confidence and knowledge to move 
from being a passive recipient of care to being an active 
partner. Empowerment needs to take place simultane-
ously both at the population and the individual level. It 
therefore requires a cultural change, involving a change 
in the balance of power to recognise chronic patients 
as experts in their own care by experience and also “co-
managers” of their condition in partnership with health 
professionals” [20].
This change can be achieved by focusing on educa-
tion and training for all stakeholders, patients, health 
professionals and institutions. Revitalising public health 
requires rethinking education of health professionals to 
produce a more flexible, multi-skilled workforce able 
to meet the growing challenges and to support patient 
empowerment and consumers with the adequate level 
of health literacy, and fostering communication, man-
agement and leadership capacities at all levels. It will be 
thus possible to promote innovative and high-quality, 
truly patient-centred, sustainable health systems of the 
future.
b) How is a patient empowered?
Taking control of one’s own health involves more than 
just gaining a voice. For this reason, there are many 
ways in which patients can be empowered. The follow-
ing are often identified as key ones:
Health literacy, education and capacity-building. 
– Although empowerment involves much more than 
becoming an educated/informed patient, the right in-
formation and resources are fundamental tools for 
empowerment. The WHO [21] highlighted that lim-
ited health literacy negatively affects health, reinforces 
health inequalities, especially among poorer popula-
tions, and leads to higher healthcare system costs. Im-
proving health literacy and education not only empow-
ers patients but also contributes to the sustainability of 
healthcare systems.
Health literacy is a dynamic, interactive process 
whereby the information is critically analysed and ap-
plied to influence or take action to change the com-
munity. Patients need to know where to find reliable 
information from trustworthy sources. In this sense, 
the European Commission’s recent paper on Digital 
Health Literacy focused on the use of the Internet to 
search for health-related information. The EU eHealth 
Action Plan 2012-2020 – Innovative Healthcare for the 
21st Century also looks at how greater access to ser-
vices and information and the use of social media for 
health can strengthen patient-centred care and empow-
erment [22].
Health literacy addresses the environmental, po-
litical and social factors that determine health. Health 
education also encompasses capacity-building and aims 
to influence not only individual lifestyle decisions, but 
also raises awareness of the determinants of health, and 
encourages individual and collective actions which may 
lead to a modification of these determinants. Health 
education is achieved therefore, through methods that 
go beyond information diffusion and entail interaction, 
participation and critical analysis. Such health education 
leads to health literacy, leading to personal and social 
benefit by enabling effective community action, and 
contributing to the development of social capital [23].
Patient organisations often fulfil the task of ensuring 
education for patients and healthcare professionals by 
developing and often funding helplines, information 
and developing ad hoc trainings for patients so that 
they can become fully-fledged partners in decision-
making and/or in the relations with other actors they 
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come across in their healthcare pathway. In the field 
of rare diseases, trainings such as the EURORDIS 
Open Academy (www.eurordis.org/content/eurordis-
open-academy#tabs-1) or the EUPATI programme, are 
extremely important to build patients capacities and 
to allow them to understand the scientific landscape, 
to discuss with researchers, medical staff and industry 
on equal foot, or to develop those personal skills that 
are essential for the interactions with other healthcare 
stakeholders. 
Umbrella patient organisations that acting at the na-
tional level also play a crucial role in capacity-building. 
By pooling patients across the country together and act-
ing as a single voice, national patient organisations are 
able to contribute to empowerment at all three levels 
(micro, macro and policy). In particular, they are able 
to provide input for appropriate policy, research and 
health provision that responds to the needs of the con-
stituent population. In addition, this collective national 
grouping facilitates the interaction with similar group-
ings from other countries in order to exchange best 
practices and learn from the successes and challenges 
experienced in different contexts.
Shared decision-making and Integration of pa-
tients’ views. – Shared decision making (SDM) has 
been defined as: “an approach where clinicians and pa-
tients share the best available evidence when faced with 
the task of making decisions, and where patients are 
supported to consider options and to achieve informed 
preferences [24]”. In sum, shared decision-making is 
the process by which a clinician and a patient jointly 
make a health decision after discussing options, poten-
tial benefits and harms, and considering the patient’s 
values and preferences. At its core, shared decision-
making rests on accepting that individual self-determi-
nation is a desirable goal and that clinicians need to 
support patients to achieve this goal, wherever feasible. 
Self-determination in the context of SDM does not 
mean that individuals are abandoned. SDM recognises 
the need to support autonomy by building good rela-
tionships, respecting both individual competence and 
interdependence on others.
The key to understanding this concept is to recognise 
that in every medical or health decision, there are at 
least two sources of expertise for making a good choice. 
The clinician has had lengthy and extensive medical 
training; but only the patient knows his/her attitude to 
risk, how the illness is experienced in his/her particu-
lar social circumstances, and his/her values and prefer-
ences. Therefore, “the Patients as Partners concept (…) 
takes patient engagement even further by considering 
the patient as a full-fledged member of the healthcare 
team (…) Chronically ill patients develop experiential 
knowledge that can enhance their self-managed care 
and complement the scientific knowledge of health-
care professionals. In other words, from a patient’s 
perspective, quality healthcare decisions are based on 
two complementary forms of knowledge: the scientific 
knowledge of health professionals and the patient’s own 
experiential knowledge” [25]. 
An example of success in pursuing the integration of 
patients’ views is the recent creation of the European 
Patient Advocacy Groups (ePAGs, www.eurordis.org/
content/epags), patient representatives ensuring that 
patients are fully represented in the governance of each 
and every European Reference Networks, promoting 
and encouraging a patient-centric approach in both de-
livery of clinical care, service improvement and strate-
gic development and decision-making, in line with the 
above-mentioned Addendum of the EUCERD Recom-
mendation’s on ERNs.
In sum, the approach to healthcare where health pro-
fessionals make all decisions with little or no input from 
the patient has evolved over the last decades towards 
a patient model whereby individual patients’ needs, 
values, and experiences are crucial for personalised 
and person-centred healthcare. Patient participation or 
engagement is recently receiving greater attention, as it be-
comes increasingly evident that it can be an innovative and 
viable approach to ensuring appropriate care in the current 
environment strained by limited resources. 
Support to self-care and self-management. – Self-
care is increasingly viewed as a core component of the 
management of long-term conditions. The majority of 
care for chronic conditions is provided and coordinated 
by the people themselves, with the support of family 
members and carers, at home and in the community 
[26]. This also applies to people living with a rare dis-
ease and their families.
Self-management is defined as the ability of the pa-
tient to deal with all that a chronic illness entails, in-
cluding symptoms, treatment, physical and social con-
sequences, and lifestyle changes. For self-management 
to be effective, it needs to rely on the proactive engage-
ment of physicians, patients, care-givers, and health 
care organisations. The coordinated approach between 
all those involved will enhance patient care and more ef-
fectively treat patients with multiple chronic conditions. 
Self-management plays a crucial role for those patients 
who suffer from multiple chronic conditions or multi-
symptomatic diseases, such as the majority of rare 
diseases. With effective self-management, the patient 
can monitor his or her condition and make whatever 
cognitive, behavioural, and emotional changes needed 
to maintain a satisfactory quality of life [27]. Many 
prevalent chronic conditions, including rare diseases, 
although unique in their own attributes and demands, 
share common challenges associated with their man-
agement, that include dealing with symptoms and dis-
ability; monitoring physical indicators; managing com-
plex medication regimens; maintaining proper levels of 
nutrition, diet, and exercise; adjusting to the psycho-
logical and social demands, including difficult lifestyle 
adjustments; and engaging in effective interactions with 
health care providers. 
For people living with a rare disease, however, self-
management (and the collective support required to 
achieve it) is far from being the reality. In the survey 
Juggling rare diseases and daily lives [11], one of the high-
est needs expressed is the “request for services that help 
patients to maintain their autonomy and help self-man-
agement of the disease, including rehabilitation services 
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and therapies (48%), psychological support (47%), sup-
port to adapt house to the needs (30%), medical devices 
(28%) and adapted transports (23%). Autonomy is par-
ticularly at risk in cases in which the person needs help 
with their most basic and private needs or when the im-
pairment affects his/her ability to communicate” [11].
Self-management support allows the development of 
confidence, self-efficacy and skills to control daily life, 
provided that is carried out according and in respecting 
each person’s individual needs and preferences. Self-
management support, as a consequence, has a positive 
impact on the healthcare systems as it helps make best use 
of all available resources by improving adherence, reducing 
hospitalisation and emergency visits, and improving health 
outcomes [10].
Self-management programs such as the Arthritis Self-
Management Program (ASMP) and the Diabetes Self-
Management Program in the US demonstrated the fea-
sibility of self-management intervention programmes, 
leading to positive health outcomes, many of which per-
sist for years, with an added benefit of reduced health 
care costs [28, 29].
DISCUSSION
How to empower rare disease patients in sustainable 
healthcare systems
From what is illustrated above it emerges clearly that 
achieving patient empowerment is a key enabler in the 
process of creating sustainable and equitable systems 
for all, thus addressing the challenges faced by modern 
healthcare systems (demographic shift, increased burden 
of chronic diseases, increasing costs of treatments and 
care, limited access to innovative care, intra-European 
difference, etc.). The European Patients’ Forum’s latest 
campaign highlight five elements of patient empower-
ment (1. education, 2. expertise, 3. equality, 4. experience 
and 5. engagement) which demonstrate that patients are 
active people who can, if supported and according to 
their individual capabilities and situation, make a differ-
ence for the sustainability of healthcare systems (www.
eu-patient.eu/campaign/PatientsprescribE/).
This is recognised in the 2014 Communication from 
the European Commission on effective, accessible and 
resilient health systems where the impact of patient em-
powerment on health systems is explained in terms of:
1) effectiveness: positive clinical outcomes, improved 
quality of life, better use of health services, which re-
spond the needs of patients;
2) access: more transparency and understanding of 
the healthcare system by the patient can ensue in bet-
ter access to healthcare; also, empowered patients can 
advocate for improved access; 
3) resilience: information flow in the system has proved 
to improve the resilience of health systems [30].
In fact, an important element is that results of patient 
empowerment beginning at “micro level” then produces 
“macro effects”. 
At the micro (individual) level, the first benefit expe-
rienced by the patient is improved health (i.e. quantity 
and quality of life years gained): by empowering pa-
tients it is be possible to achieve results in terms of more 
appropriate and effective use of healthcare resources, 
lower use of drugs, less health inequalities among pop-
ulation, less treatment errors and an increased use of 
preventive services. In addition, as highlighted in the 
EMPATHiE project, additional outcomes of patient 
empowerment include greater patient satisfaction, pro-
fessional satisfaction, increased quality of life, improved 
clinical outcomes and better use of health services [31]. 
Patients who are empowered to make decisions about 
their health have greater satisfaction because the cho-
sen treatment or screening option better reflects their 
personal preferences, needs and values and the cost-
benefit relation that the patient and her/his family see 
as appropriate. In the long-term this leads to consid-
erable advantages in terms of psychological state and 
quality of life, as well as in savings for health service 
costs. For the adult population this also translates into 
workplace productivity gains, experienced by patients, 
their family and their employers. 
At the macro level, the empowerment of patients and 
their representatives has a positive impact on the qual-
ity of health and social services. There is a political ac-
knowledgement at EU level that patients should be “at 
the centre” of healthcare systems and that to achieve 
this, patients’ representative organisations should be 
part of healthcare-related policy and decision-making 
[32]. Collective patient empowerment, through the 
meaningful involvement of patient representatives and 
organisations in health policy, service design and evalu-
ation with the aim to improve the system, will be the 
key to fostering patient empowerment in all EU health 
systems and will lead to public spending on healthcare 
that is more explicitly linked to population health needs.
At the highest (or policy) level, through their represen-
tative organisations, patients can offer guidance to de-
cision-makers on quality care that is also cost-effective, 
and can therefore contribute to the debate for re-shap-
ing healthcare systems. Over the years, patient groups 
have been giving individual patients a stronger voice. 
They are also involved in disease education for patients 
and healthcare professionals by providing helplines, 
emotional support, information, access to treatment 
and generally fighting for patients’ rights. And they con-
duct advocacy discussions about the healthcare system 
and play a crucial role to show real and concrete need 
of patients and citizens.
By their individual and collective actions, empowered 
patients have therefore a crucial role in promoting ac-
tions that lead to reduction of inequalities by correcting 
social injustices affecting the patients themselves and 
by offering them back to society [19]. Patient empow-
erment thus helps reduce the multiple vulnerabilities 
(physical, moral, social and economic) and proposes a 
new concept of collective and collaborative production 
of common goods, which needs collective and collabor-
ative action, in order to make the best possible choices 
for all. 
Therefore, patient empowerment addresses the serious 
unmet social needs of people living with a rare disease 
and their families which affect their dignity, autonomy 
and other fundamental human rights expressed in the 
Universal Declaration of Human Rights and in the UN 
Convention of the Rights of Persons with Disabilities.
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In this sense, “sustainable” is what ensures equity of 
access so as to fulfil the human rights of people whose 
needs are often seriously unmet, in order to make them 
empowered citizens. Only with dignified and fulfilled 
citizens a society can be said sustainable.
CONCLUSIONS 
Achieving patient empowerment is a key enabler in 
the process of creating sustainable and equitable sys-
tems for all. To help this process, a number of recom-
mendations were made a few years ago through the 
EUROPLAN project (www.europlanproject.eu). Pa-
tient empowerment was a specific area addressed in the 
Recommendations for National Plans and Strategies 
for Rare Diseases Conferences developed by EURO-
PLAN [33] and in the 15 EUROPLAN National Con-
ferences [34].
Based on the above and on other activities highlight-
ed in this policy brief, including those carried out by 
EURORDIS and other patient groups, it appears that 
a number of potential initiatives strengthen patient em-
powerment in the rare disease community and deserve 
being supported, notably:
• Ensure an active role and effective engagement of 
patients at all key decision-making points at the na-
tional/regional/local level (“nothing about me without 
me”). Specifically, but not exhaustively: 
-  Involve patients in Steering Committees or equiva-
lent bodies overseeing the implementation and/
or the monitoring /evaluation of National Plans or 
Strategies for rare diseases;
-  Include patients in the evaluation of the opportu-
nity/costs of policy planning on RDs – basically any 
time “benefit” is to be assessed;
-  Recognise the role of patients/patient representa-
tives in hospitals, centres of expertise and other lo-
cal decision-making bodies relevant for specific dis-
eases or groups of diseases.
• Integrate patients in clinical trial design focusing on 
meaningful endpoints and patient outcomes.
• Promote patients’ training, educational and capacity 
building initiatives, so to allow patients to become 
fully-fledged partners in decision-making. On clini-
cal trial design for example, training is extremely im-
portant to allow patients to understand the scientific 
landscape and to discuss with researchers, medical 
staff and industry on equal foot. 
• Support patient empowerment initiatives through 
public money in order to guarantee an effective con-
tribution of patients as equal partners.
• Improve awareness-raising on the role of patients in 
the decision making process to improve public per-
ception. 
• Guarantee that the progress made in empowering 
patients and in rare disease policy in general be main-
tained in spite of changes in government and volatile 
political backgrounds. 
• Ensure that medical and paramedical staff receive 
adequate professional training to help them identify 
and treat rare diseases, but also to help them interact 
with patients in a context of shared decision-making.
• Promote the creation of telephone help lines that play 
an essential role for the provision of general and spe-
cific information on rare diseases, with the promo-
tion of best practice exchanges and quality assurance 
initiatives.
• Develop or reinforce the role of “Case managers” 
who could address the specific range of needs of the 
rare disease patient and help them navigate the com-
plex environment.
• Promote self-management initiatives adapted to peo-
ple living with rare diseases, tailored to each disease 
or disease group, ideally designed in the context of 
European Reference Networks, to accompany dis-
ease-specific ‘strategies of care’ or clinical guidelines.
• Adapt social services so that they cater to the needs 
of patients with RDs and promote the inclusion of 
rare disease specificities in national social policies – 
allow integration of people living with rare diseases in 
school, workplace and social life in general.
There are currently a number of such initiatives that 
qualify as promoting patient empowerment and thus 
promoting more sustainable healthcare systems, how-
ever these are scattered and unevenly applied across the 
EU countries and regions.
It may therefore be argued that the ultimate recom-
mendation could be to develop a roadmap or strategy 
at EU level on patient empowerment that includes the 
above specific recommendations and takes stock of ex-
periences and best practices existing across the EU or 
beyond, encouraging their uptake in a comprehensive 
and systematic framework. Such a strategy would be 
applied to the appropriate level(s) of governance (Eu-
ropean, national or local) to ensure that patient empow-
erment becomes a reality and contributes to improved 
healthcare across Europe’s national systems.
In conclusion, such a strategy would be one where-
by the attainment of the highest possible standards of 
health depends on a comprehensive, holistic approach 
which goes beyond the traditional curative care, involv-
ing patients, communities, health providers and other 
stakeholders. This holistic approach should empower 
individuals and communities to take actions for their 
own health, foster equality in partnership for public 
health, promote intersectoral action to build healthy 
public policies and create sustainable health systems in 
the society, where all actors are fulfilled human beings 
and unmet needs are addressed in compliance with fun-
damental human rights.
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